oseltamivir has been researched along with Diabetes Mellitus, Adult-Onset in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daneshpazhooh, M; Isazade, A; Noormohammadpour, P; Soori, T | 1 |
| Blumentals, WA; Orzeck, EA; Shi, N | 1 |
2 other study(ies) available for oseltamivir and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deprescriptions; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Humans; Hypertension; Immunoglobulins, Intravenous; Immunologic Factors; Iran; Lopinavir; Male; Mycophenolic Acid; Oseltamivir; Pandemics; Pemphigoid, Benign Mucous Membrane; Pneumonia, Viral; Prednisolone; Ritonavir; Rituximab; SARS-CoV-2; Tomography, Spiral Computed | 2020 |
Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Delivery of Health Care; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Influenza, Human; Insurance Claim Review; Male; Managed Care Programs; Middle Aged; Oseltamivir; Otitis Media; Respiratory Tract Diseases; Retrospective Studies; Risk; Treatment Outcome | 2007 |